A protein found in the starlet sea anemone Nematostella vectensis defends against viruses by doing the opposite of what its closest counterpart does in humans. The protein, called CARDIB, normally keeps immune genes switched off, yet animals that lack it fail to fight off viral infections. That dual role, acting as both a brake and a shield, represents an evolutionary path for antiviral defense that has no known parallel in vertebrate biology.
Why a Brake-and-Shield Protein Rewrites Antiviral Assumptions
In humans and other mammals, the protein MAVS sits at the center of antiviral signaling. When a virus enters a cell, sensors called RIG-I-like receptors detect foreign RNA and activate MAVS, which then switches on inflammatory defense genes. MAVS is an accelerator: it ramps up the immune response. CARDIB shares the same structural blueprint as MAVS, but its default job is the reverse. It represses immune genes at baseline in Nematostella vectensis, keeping antiviral pathways quiet until they are actually needed.
That arrangement matters because sea anemones live in estuaries where they are constantly bathed in water teeming with bacteria and viruses. Running a full immune response around the clock would be energetically expensive and potentially destructive to the animal’s own tissues. CARDIB appears to solve that problem by suppressing unnecessary activation while still standing ready to mount a defense when a genuine threat arrives. The hypothesis that this baseline repression evolved specifically to manage the costs of living in a high-pathogen environment is testable: researchers could measure fitness differences in CARDIB-deficient anemones across varying salinity and viral exposure conditions, using the estuarine mesocosm datasets already deposited for this line of work.
Sea anemones are cnidarians, a group that diverged from the lineage leading to humans roughly 600 million years ago. Finding a MAVS-like protein that works in reverse at such an early branch of the animal tree suggests that the “always-on accelerator” model familiar from mammalian immunology is not the only viable strategy. Instead, baseline repression coupled with rapid activation may represent an older, alternative solution to the same problem: how to live alongside viruses without being destroyed by them.
CARDIB’s Dual Function and the Data Behind It
The central findings come from a study published in Nature Ecology and Evolution, with collaboration from the Reitzel Lab at UNC Charlotte. The research team showed that CARDIB is MAVS-like by sequence and architecture, confirmed that it represses immune genes under normal conditions, and demonstrated that it is required for effective antiviral defense after viral challenge. Animals lacking functional CARDIB accumulated higher viral loads when exposed to natural estuarine water in a mesocosm experiment conducted in a South Carolina estuary.
The raw sequencing data underlying these conclusions are publicly available. RNA-seq reads from the CARDIB signaling experiments are deposited under NCBI BioProject PRJNA1250240, while total RNA-seq data from the mesocosm study sit under NCBI BioProject PRJNA1262874. Those datasets allow independent researchers to verify the viral load comparisons and community composition claims, and to test alternative models of how CARDIB shapes the broader microbial ecosystem associated with Nematostella.
This work did not emerge in isolation. Earlier experiments had already established that Nematostella vectensis possesses functional RIG-I-like receptor responses to double-stranded RNA analogs, confirming that the upstream sensors feeding into a MAVS-like pathway are active in cnidarians. Separate research showed that the cyclic dinucleotide 2’3′-cGAMP can trigger broad antiviral and antibacterial responses in the same species through a STING-related signaling axis. Together, these studies reveal that sea anemones possess multiple antiviral systems, some shared with mammals and some organized in fundamentally different ways.
One pathway that does not appear to compensate for CARDIB is RNA interference. Recent work characterizing RNAi in Nematostella found partial target silencing but no small RNA amplification, meaning the anemone’s RNAi machinery is limited compared with the amplification-driven antiviral RNAi seen in insects and plants. That gap makes CARDIB’s role even more significant: without a strong RNAi backup, the CARDIB–RLR axis may carry a larger share of the antiviral workload in these animals.
How CARDIB Flips the MAVS Script
At the molecular level, CARDIB and MAVS share recognizable domains, including a caspase activation and recruitment domain (CARD) that typically mediates protein–protein interactions in immune signaling. In vertebrates, RIG-I-like receptors bind viral RNA and then engage MAVS through CARD–CARD contacts, forming large signaling platforms on mitochondrial membranes. These assemblies recruit kinases and transcription factors that ultimately drive interferon and inflammatory gene expression.
CARDIB appears to use the same architectural toolkit for a different logic. Under homeostatic conditions, it keeps antiviral transcription factors in check and maintains low expression of immune effector genes. When viral RNA is detected, CARDIB is required for the rapid release of this repression and for full induction of downstream antiviral programs. Knockout or knockdown experiments show that without CARDIB, many of the genes normally activated upon infection are blunted, even though the upstream sensors remain present.
This “repressed-until-needed” configuration offers a conceptual contrast to the vertebrate system, where much of the regulation occurs through inducible activation rather than constitutive suppression. In Nematostella, the default state is silence, and CARDIB is both the enforcer of that silence and the gatekeeper that must be present for a robust response. The same molecule therefore underlies both immune restraint and immune competence.
Ecology, Evolution, and the Cost of Immunity
Placing CARDIB in its ecological context helps explain why such a configuration might have evolved. Estuarine environments are dynamic, with fluctuating salinity, temperature, and nutrient loads, and they host dense microbial communities. For a small, soft-bodied animal like Nematostella, indiscriminate immune activation could damage tissues, disrupt symbiotic relationships, or divert energy away from growth and reproduction.
By enforcing baseline repression, CARDIB likely reduces chronic inflammation and prevents spurious responses to harmless or beneficial microbes. Yet the mesocosm experiments show that this restraint does not come at the expense of protection: when viruses in natural seawater challenge the animals, CARDIB-dependent pathways are essential for containing infection. The protein therefore embodies a trade-off between vigilance and restraint that is tuned to the animal’s habitat.
From an evolutionary perspective, the presence of a MAVS-like scaffold in a cnidarian that uses it in such a different way suggests that innate immune architectures are more flexible than previously appreciated. Rather than a single, linear trajectory from simple to complex, antiviral systems may have diversified early, with different lineages experimenting with distinct balances of activation and repression. CARDIB represents one such experiment that has persisted for hundreds of millions of years.
Implications Beyond Sea Anemones
Although CARDIB itself has no direct counterpart in humans, its behavior raises broader questions for immunology. One is whether vertebrates also harbor unrecognized “brake-and-shield” molecules that both suppress baseline activity and enable effective responses. Another is how widespread similar strategies are across invertebrates, especially in groups that inhabit microbially rich environments such as coral reefs, hydrothermal vents, or coastal sediments.
The discovery also underscores the importance of studying non-model organisms. Nematostella has emerged as a powerful system for dissecting ancient immune pathways precisely because it sits outside the traditional bilaterian models yet retains many conserved components. Insights from this cnidarian are already reshaping views of RIG-I-like receptors, STING signaling, and RNAi, and CARDIB adds a new layer to that rethinking.
Finally, the work highlights the value of open data. By making RNA-seq and mesocosm datasets publicly accessible, the researchers invite others to probe the limits of their conclusions, test alternative hypotheses about CARDIB’s network of interactions, and explore how viral communities respond when this key regulator is removed. As more such datasets accumulate across diverse species, comparative analyses may reveal whether CARDIB is a one-off innovation or part of a broader, underappreciated repertoire of antiviral strategies that rely on controlled repression as much as on rapid activation.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
